NZ proposal to reduce price and subsidy for Humira and HumiraPen
New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on a provisional agreement with the local subsidiary of US drugmaker AbbVie (NYSE: ABBV) to reduce the price and subsidy of adalimumab (Humira and HumiraPen) and to retain the same funded access criteria that currently apply to adalimumab.
The result of this proposal is that access to adalimumab for dermatology and rheumatology indications would not change from January 1, 2016, as notified on September 2015, and both etanercept (Enbrel, from Pfizer) and adalimumab would remain options to use as a first-line biologic treatment for dermatology and rheumatology indications.
In summary, the proposal is to:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze